Abstract: The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to Ehrlichia antigens. The peptide compositions comprise polypeptide sequences based on an immunogenic fragment of the Ehrlichia Outer Membrane Protein 1 (OMP-1) protein. The invention also provides devices, methods, and kits comprising such peptide compositions and useful for the detection of antibodies that bind to Ehrlichia antigens and the diagnosis of monocytic ehrlichiosis.
Type:
Grant
Filed:
November 19, 2010
Date of Patent:
September 9, 2014
Assignee:
Abaxis, Inc.
Inventors:
Rajesh K. Mehra, Kenneth P. Aron, Dennis M. Bleile
Abstract: A vaccine preparation characterized in that Neospora caninum-derived dense granule protein 7 or apical membrane antigen 1 or an immunologically active variant or derivative thereof is included in liposomes each having an oligosaccharide capable of binding to a carbohydrate recognition molecule on the surface of antigen-presenting cells on the surface of the liposome.
Type:
Grant
Filed:
September 11, 2009
Date of Patent:
September 2, 2014
Assignees:
Obihiro University of Agriculture and Veterinary Medicine, Tokai University Educational System
Inventors:
Yoshifumi Nishikawa, Naoaki Yokoyama, Naoya Kojima
Abstract: The present invention provides improved methods for producing a solution containing high molecular weight isolated Streptococcus pneumoniae 19A capsular polysaccharides. In certain methods, a fermentation culture of Streptococcus pneumoniae bacterial cells that produce serotype 19A capsular polysaccharides is fermented for less than 6 hours before the bacterial cells are lysed the capsular polysaccharides are harvested. In other methods, CO2 is supplied to the fermentation culture. Supplying CO2 to the fermentation culture includes adding bicarbonate ions to the fermentation culture, adding carbonate ions to the fermentation culture, adding mixtures of bicarbonate and carbonate ions to the fermentation culture, and overlaying the fermentation culture with CO2.
Abstract: This invention provides submicron oil-in-water emulsions useful as a vaccine adjuvant for enhancing the immunogenicity of antigens. The present invention also provides vaccine compositions containing an antigen combined with such emulsions intrinsically or extrinsically. Methods of preparing the emulsions and vaccines are also provided by the present invention.
Type:
Grant
Filed:
December 31, 2009
Date of Patent:
July 8, 2014
Assignee:
Zoetis LLC
Inventors:
Paul J. Dominowski, Ramasamy M. Mannan, Richard L. Krebs, Pamela K. Klose
Abstract: The present invention provides an oral vaccine against a bacterial infectious disease (e.g., typhoid fever, cholera, or dysentery). The oral vaccine of the present invention is a capsule formulation in which a transformed microorganism that expresses a flagellin antigen protein or that secretes a flagellin antigen protein out of the cell of the microorganism is encapsulated with an acid-resistant membrane. Examples of the microorganism include intestinal bacteria belonging to the genus Bifidobacterium, the genus Lactobacillus, the genus Lactococcus, and the like. The form of the capsule formulation may be any one of a seamless capsule formulation, a soft capsule formulation, and a hard capsule formulation.
Abstract: The present invention relates to a protein composition suitable for inducing an immune response in a vertebrate comprising 2 to 10 protein variants of a single antigen, which is the APICAL MEMBRANE ANTIGEN 1 (PfAMA1 OR AMA1) of a Plasmodium species. The antigen comprises a plurality of variable amino acid positions, wherein the amino acid sequences of said protein variants, in combination, represent both the frequency of occurrence of each amino acid at said variable amino acid positions and the linkage between the variable amino acid positions, and wherein said frequency of occurrence is at least between 10% to 20% such as 10%, 11%, 12%, 13%, . . . , 20% in the single antigen, and wherein at least 75% of the linkages between the variable amino acid position is presented by the combination of protein variants.
Type:
Grant
Filed:
December 21, 2006
Date of Patent:
June 3, 2014
Assignee:
Stichting Biomedical Primate Research Centre
Inventors:
Alan William Thomas, Clemens Hendricus Martinus Kocken, Bart Willem Faber, Edmond Joseph Remarque
Abstract: Bacillus strains that inhibit pathogenic swine E. coli and/or improve performance are provided. Inhibition of pathogenic swine E. coli decreases E. coli disease. At least one strain enhanced swine performance by improving average daily gain, feed efficiency, and feed intake. Preferred Bacillus strains are of species that are included on the GRAS, i.e., generally recognized as safe, list. Bacillus species are sporeformers and therefore are highly stable and can be fed to swine.
Type:
Grant
Filed:
June 12, 2012
Date of Patent:
May 13, 2014
Assignee:
DuPont Nutrition Biosciences ApS
Inventors:
Thomas G. Rehberger, Dorrie S. Jordan-Parrott
Abstract: The present invention relates to a method for modulating immune response in a subject, which comprises administering to the subject an effective amount of a composition comprising a yolk or yolk antibody obtained from an egg of a fowl which has been immunized using Helicobacter pylori as an antigen. In particular, the method of the invention is effective in enhancing production of IFN-?? and suppressing production of IL-4 and IL-5 in a subject. Also provided is a composition which comprises said yolk or yolk antibody in combination with polypore and chitosan.
Abstract: The present invention provides antibodies that bind to the endospore of the bacterium Clostridium difficile, methods of making such antibodies, and methods of using such antibodies, including methods of detecting C. difficile endospores.
Abstract: The present invention relates to a composition comprising a) a B subunit of Shiga toxin or a functional equivalent thereof which is able to bind the Gb3 receptor, complexed with an antigen and b) at least one ligand of CDI capable of stimulating NK T cells; and to a pharmaceutical composition and a medicament comprising said composition.
Type:
Grant
Filed:
December 26, 2007
Date of Patent:
April 1, 2014
Assignees:
Universite Rene Descartes Paris 5, Institut Curie, Assistance Publique Hopitaux de Paris, Centre National de la Recherche Scientifique-CNRS
Abstract: The invention relates to mutant strains of the genus Sphingomonas which have a mutation in at least one gene encoding a protein involved in polyhydroxybutyrate (“PHB”) synthesis that allows the mutant strains to produce PHB-deficient Sphingans. The invention is also directed to a process for preparing a clarified Sphingan solution comprising heating aqueous Sphingan solution, in particular PUB-deficient Sphingan solution, to a clarification temperature of about 30° C. to about 70° C., and treating the solution with a clarification agent and enzymes. In addition, the invention is directed to a food or industrial product comprising a PHB-deficient and/or clarified Sphingan. One particular embodiment of the invention is directed to a clarified, PHB-deficient high-acyl gellan and the processes of making thereof.
Type:
Grant
Filed:
November 1, 2010
Date of Patent:
February 18, 2014
Assignee:
C.P. Kelco U.S., Inc.
Inventors:
Stan Bower, Ellen Burke, Nancy E. Harding, Yamini N. Patel, J. Carrie Schneider, Dagmar Meissner, Neil A. Morrison, Ralph Bezanson
Abstract: Pneumococcal pilus subunit RrgB has at least three clades. Serum raised against a given clade is active against pneumococci which express that RrgB clade, but is not active against strains which express one of the other two clades i.e. there is intra-clade cross-protection, but not inter-clade cross-protection. Thus an immunogenic composition can include at least two different clades of RrgB to improve strain coverage against pilus-containing pneumococci. These multiple clades may be present in the immunogenic composition as separate polypeptides or may be fused as a single polypeptide chain.
Type:
Grant
Filed:
June 1, 2010
Date of Patent:
December 17, 2013
Assignee:
Novartis AG
Inventors:
Vega Masignani, Michele Anne Barocchi, Monica Moschioni, Paolo Ruggiero
Abstract: The purpose of the invention is to provide a novel purification system allowing the efficient and economical production and purification of a recombinant fused protein, whereby the elution time at a low temperature can be reduced, since it has been a problem to be solved in the existing purification method using dockerin and cohesin. In this purification system, a dockerin polypeptide characterized in that the 14th amino acid in the subdomain 2 of dockerin originating from Clostridium josui is substituted with another amino acid, and a method for purification of a recombinant fused protein are provided.
Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an enhanced targeting domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
Type:
Grant
Filed:
July 11, 2007
Date of Patent:
August 27, 2013
Assignee:
Allergan, Inc.
Inventors:
Lance E. Steward, Joseph Francis, Ester G. Fernandez-Salas, Marcella A. Gilmore, Shengwen Li, Kei Roger Aoki
Abstract: Novel thymidine kinase (TK1) derived peptide consisting of the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2 is employed to obtain ligands having specificity to the peptide. The ligand may be an antibody or fragment thereof and may be used in various methods and kits for health screening and the like.
Abstract: The specification discloses modified Clostridial toxins comprising an exogenous Clostridial toxin di-chain loop protease cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins; method of producing such modified Clostridial toxins, method of activating such modified Clostridial toxins and methods of activating recombinantly-expressed Clostridial toxins.
Type:
Grant
Filed:
June 27, 2008
Date of Patent:
July 16, 2013
Inventors:
Marc F. Verhagen, Dean G. Stathakis, Lance E. Steward
Abstract: Disclosed is a new and emerging serotype of Streptococcus pneumoniae designated serotype 6C, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit {?2) glucose 1 (1?3) glucose 2 (1?3) rhamnose (1?3) ribitol (5?phosphate}. This new serotype may be included in pneumococcal vaccines.
Type:
Grant
Filed:
December 28, 2006
Date of Patent:
July 9, 2013
Assignees:
The UAB Foundation, Fundacao Oswald Cruz, Instituto Adolfo Lutz
Inventors:
Moon H. Nahm, Jisheng Lin, Angela P. Brandao, Maria Cristina Brandileone
Abstract: The present invention relates to compositions for removing a biofilm formed by Staphylococcus aureus, comprising a bacteriophage, such as Myoviridae family T4-like phage genus bacteriophage (Accession No: KCTC 11153BP, SAP-1) or Podoviridae family ?29-like virus genus bacteriophage (Accession No: KCTC11154BP, SAP-2), and lytic protein derived therefrom, that destroys the biofilm. Also disclosed are pharmaceutical compositions for the treatment of diseases caused by Staphylococcus aureus capable of forming biofilm.
Type:
Grant
Filed:
September 12, 2008
Date of Patent:
February 19, 2013
Assignee:
iNtRON Biotechnology, Inc.
Inventors:
Seongjun Yoon, Yunjaie Choi, Se Yung Lee, Jeesoo Son, Sooyoun Jun, Sanghyeon Kang
Abstract: Transgenic microbes with an altered electrogenic efficacy, biofilms comprising such microbes, and microbial fuel cells comprising such microbes are provided. The microbial fuel cells can be operated as monitors, filtration devices, and sensors.
Type:
Grant
Filed:
February 23, 2010
Date of Patent:
January 15, 2013
Assignees:
Bacterial Robotics, LLC, University of Cincinnati
Inventors:
Jason E. Barkeloo, Daniel J. Hassett, Randall T. Irvin
Abstract: The present invention provides non-toxic Gram-negative bacteria. In particular, the present invention provides viable Gram-negative bacteria (e.g., E. coli) substantially lacking lipopolysaccharide (LPS, endotoxin) within the outer membrane. The present invention further provides methods of generating viable non-toxic Gram-negative bacteria and uses thereof. The present invention also provides compositions and methods for inducing immune responses and for researching and developing therapeutic agents.
Type:
Grant
Filed:
January 19, 2007
Date of Patent:
November 6, 2012
Assignee:
Research Corporation Technologies, Inc.
Inventors:
Ronald Wesley Woodard, Timothy Charles Meredith, Parag Aggarwal